Baker Brothers Advisors

Baker Brothers Advisors

Baker Brothers Advisors was founded in 2000 by brothers Julian and Felix Baker, both holding PhDs in molecular biology and immunology. The firm evolved from a family partnership managing inherited wealth into a registered investment adviser managing the largest dedicated public biotechnology portfolio in the world. Its structure as an outsourced, non-marketing asset manager for a single multi-billion-dollar pool of family and affiliated capital gives it a time horizon unavailable to quarterly-redemption funds. The firm's strategy centers on concentrated, long-only public equity positions in clinical-stage and commercial biotechnology companies. It avoids the generalist mandate of crossover funds, committing instead to deep technical due diligence on therapeutic platforms. Its 13F filings, widely tracked as a sector benchmark, reveal enduring positions: Seagen, where Baker Brothers was the largest shareholder before its $43B acquisition by Pfizer in 2023, and BeiGene, the China-rooted oncology developer where it held over 20% of shares outstanding for years. The firm also participates in select PIPEs and follow-on financings, using its balance sheet to anchor rounds that require patience generalist investors cannot supply. Baker Brothers operates from a single office in New York. The firm does not disclose its total asset base or team size, and it maintains no public-facing website content as of mid-2026. Its 13F equity portfolio alone has exceeded $20B in reported market value during recent filings, making the vehicle larger than many well-known biotech dedicated hedge funds combined. The Bakers also maintain a significant philanthropic presence through the Baker Brothers Foundation, which funds biomedical research and Jewish community causes in the New York area. In September 2023, the firm's largest disclosed position, Seagen, was acquired by Pfizer for $43B, representing one of the largest biotechnology exits in history and a validating moment for the firm's multi-decade thesis on antibody-drug conjugates. What distinguishes Baker Brothers structurally is its researcher-operator model. Unlike platform hedge funds where portfolio managers answer to a risk committee, Julian and Felix Baker are the investment committee. Both hold PhDs and maintain active scientific networks across academia and industry, effectively sourcing proprietary insights through peer-review-caliber analysis rather than Wall Street research coverage. This creates a fund that behaves less like a traditional asset manager and more like an evergreen, insider-led biotech holding company.